Fecha de publicación: 10/10/2024 Fuente: PubMed "hive" Immunol Allergy Clin North Am. 2024 Nov;44(4):595-613. doi: 10.1016/j.iac.2024.07.001. Epub 2024 Aug 26.ABSTRACTAntihistamine refractory chronic spontaneous urticaria (CSU) has a prevalence of up to 50%. Anti-immunoglobulin E (IgE) therapies have revolutionized management of CSU, yet refractory cases persist, suggesting a role for biologic agents that impact alternative routes of mast cell stimulation independent of cross-linking at FcεR1. This review addresses anti-IgE and Th2-targeted therapies in the management of CSU. In addition, we explore novel treatments targeting alternative pathways of mast cell activation including MAS-related G protein-coupled receptor-X2 and sialic acid-binding immunoglobulin-like lectin-6, inhibiting intracellular signaling via Bruton's tyrosine kinase, and disrupting KIT activation by SCF.PMID:39389712 | DOI:10.1016/j.iac.2024.07.001